Dehydroepiandrosterone

규격

53-43-0CAS 번호

200-175-5EC 번호

(3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-oneIUPAC 명칭

C19H28O2화학식

288.4 g/mol분자량

Dehydroepiandrosterone; DHEA; PRASTERONE; 53-43-0; Dehydroisoandrosterone; Androstenolone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Intrarosa; Prasterona; 3-beta-Hydroxy-5-androsten-17-one; Prasteronum; Vaginorm; 5,6-Dehydroisoandrosterone; Biolaif; EM-760; DTXSID4020379; NSC-9896; Androst-5-en-17-one, 3-hydroxy-, (3beta)-; NSC9896; 459AG36T1B; (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one; DTXCID40379; CHEBI:28689; Fidelin; Prastera; Natrol dhea; Enzymatic therapy; GL701; (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta(a)phenanthren-17-one; Prasterone, 3 alpha; prasterone and ibuprofen; RefChem:55906; 5 Androsten 3 ol 17 one; DHEA (Dehydroepiandrosterone); Therapeutic Dehydroepiandrosterone; A14AA07; G03XX01; 5 Androsten 3 beta hydroxy 17 one; 5-Androsten-3-beta-hydroxy-17-one; 200-175-5; trans-Dehydroandrosterone; Diandrone; Psicosterone; 17-Chetovis; Prestara; Andrestenol; 5-Dehydroepiandrosterone; Dehydro-epi-androsterone; Siscelar plus; (+)-Dehydroisoandrosterone; 5,6-Didehydroisoandrosterone; dehydroepiandrosterone (dhea); Epiandrosterone, 5-dehydro-; Caswell No. 051F; 5,6-Dehydroisoandrostorone; 3beta-hydroxy-5-androsten-17-one; Astenile; CCRIS 3277; Deandros; (3-beta)-3-Hydroxyandrost-5-en-17-one; DEHYDROISOANDOSTERONE; GL 701; dehydroepiandosterone; EPA Pesticide Chemical Code 126510; 5-Androsten-3beta-ol-17-one; NSC 9896; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; (3beta)-3-hydroxyandrost-5-en-17-one; Androst-5-en-17-one, 3-beta-hydroxy-; CHEMBL90593; D5-Androsten-3beta-ol-17-one; Androst-5-ene-3beta-ol-17-one; 3beta-Hydroxy-D5-androsten-17-one; 3-beta-hydroxyandrost-5-en-17-one; (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-3,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one; Dehydro Epiandrosterone; AND; Prasterone [INN]; MFCD00003613; Prasteronum [INN-Latin]; Prasterona [INN-Spanish]; CAS-53-43-0; (1S,5S,11S,15S,2R,10R)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0<2,7>.0<11,15> ]heptadec-7-en-14-one; SMR000059075; Androst-5-en-17-one, 3.beta.-hydroxy-; SR-01000075815; Prasterone [USAN:INN]; EINECS 200-175-5; Dehydro Epiandrosterone (1.0 mg/mL in Acetonitrile); BRN 2058110; 5-Androsten-3.beta.-ol-17-one; Anastar; Inflabloc; Aslera; UNII-459AG36T1B; Fidelin T; Androst-5-en-17-one, 3-hydroxy-, (3b)-; DHEA; Prasterone; NCGC00093802-04; NCGC00093802-06; Biolaif (TN); Androst-5-en-17-one, 3beta-hydroxy-; dehydroepiandrostenedione; 5-dehydro-Epiandrosterone; Prasterone (USAN/INN); trans-de-hydroandrosterone; PRASTERONE [USAN]; bmse000665; EC 200-175-5; Dehydroisoandrosterone(Dhea); PRASTERONE [MART.]; Prasterone, (3.alpha.)-; Androsten-3beta-ol-17-one; PRASTERONE [WHO-DD]; Androst-5-en-17-one, 3-hydroxy-, (3-beta)-; BIDD:PXR0080; Lopac0_000368; SCHEMBL24156; 4-08-00-00994 (Beilstein Handbook Reference); MLS001066350; MLS001333231; MLS001333232; MLS001424274; orb180847; 5-Androsten-3B-ol-17-one; D5-Androsten-3b-ol-17-one; GTPL2370; Androst-5-ene-3b-ol-17-one; PRASTERONE [ORANGE BOOK]; SCHEMBL27464949; 3b-Hydroxyandrost-5-en-17-one; 5-Androsten-3-beta-ol-17-one; MSK2264; 3b-Hydroxy-D5-androsten-17-one; 3beta-Hyroxyandrost-5-en-17-one; DEHYDROEPIANDROSTERONE [MI]; EL-10; HMS2052P11; HMS2090C04; HMS2232K11; IM 28; trans-Dehydroandrosterone, >=99%; 3-beta-hydroxy-5-androsten-17-on; IPL-1001; 3beta-hydroxy-androst-5-en-17-one; 3beta-Hydroxyandrost-5-ene-17-one; Tox21_111222; Tox21_201996; Tox21_302761; Androst-5-en-3.alpha.-ol-17-one; BDBM50223368; CMC_13435; Delta5-androsten-3-beta-ol-17-one; DL-373; GL-701; LMST02020021; MSK2264-100A; PB-007; s2604; SBB012501; DEHYDROEPIANDROSTERONE [VANDF]; 3.beta.-Hydroxyandrost-5-en-17-one; 5-Androsten-3beta-ol-17-one; DHEA; AKOS007930299; AKOS015951378; MSK2264-1000A; Tox21_111222_1; CCG-101190; CS-1667; DB01708; FD12003; GS-0906; IP-1001; NC00440; SH-K-04828; NCGC00093802-09; NCGC00093802-14; NCGC00256412-01; NCGC00259545-01; (3beta)-3-Hydroxyandrost-5-ene-17-one; AC-28716; HY-14650; NCI60_042215; Prasterone (DHEA; Dehydroepiandrosterone); ST069381; (3beta)-3-hydroxy-Androst-5-en-17-one; EU-0100368; NS00000508; Androst-5-en-17-one, 3beta-hydroxy- (8CI); C01227; D 4000; D-0340; D08409; (3alpha,8alpha)-3-hydroxyandrost-5-en-17-one; AB00375810-06; AB00375810_09; Dehydroepiandrosterone (DHEA), 1mg/ml in Methanol; Q408376; SR-01000075815-1; SR-01000075815-4; BRD-K41256143-001-12-7; (3beta,16alpha)-3,16-dihydroxy-androst-5-en-17-one; Androst-5-en-17-one, 3-hydroxy-, (3beta)- (9CI); 1A9D2040-240C-427D-ADE4-0CB700B785CB; Dehydroepiandrosterone Solution in Acetonitrile, 1000ug/mL; Dehydroepiandrosterone Solution in Acetonitrile, 100ug/mL; Prasterone (DHEA; Dehydroepiandrosterone) 1.0 mg/ml in Acetonitrile; (1S,2R,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one; (3S,8R,10R,13S)-3-Hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one; 105597-37-3동의어